## Long -term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. The aim of this study was to determine the prevalence of HBV S gene mutations in liver transplant recipients who developed recurrent hepatitis B d
Emergence of hepatitis B virus S gene mutant in a liver transplant recipient
✍ Scribed by Elisabetta Cariani; Antonella Ravaggi; Elisabetta Tanzi; Luisa Romanò; Gianfranco Fiordalisi; Giorgio Bellati; Lucio Caccamo; Dinangelo Galmarini; Alberto Albertini; Alessandro Zanetti
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 569 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Immunological and genomic analysis of the “a” determinant was carried out in seven patients with concurrent HBsAg and anti‐HBs, four of whom were immunized against hepatitis B virus at liver transplant, two with histologically characterized chronic hepatitis B virus infection, and one HBsAg healthy carrier. The immune reactivity of the HBsAg “a” determinant was evaluated by binding to specific monoclonal antibodies, and the corresponding genomic sequence was studied by differential hybridization in microtiter plates and nucleotide sequence analysis. A double mutation generating an amino acid change (glycine to lysine) at residue 145, able to impair recognition by monoclonal antibodies, was observed in the post‐transplant serum from one patient. No significant alteration of the “a” determinant sequence or reactivity was detected in the other patients.
Amino acid residue 145 appears therefore to be critical for the recognition by anti‐HBs antibodies. A previously undescribed glycine to lysine substitution at this level interferes with the immune reactivity of the “a” determinant. © Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
To determine the safety and efficacy of ganciclovir usually experience progressive liver disease over an treatment of hepatitis B virus (HBV) infection after liver accelerated time course and pose a difficult managetransplantation, nine patients (seven males, two females; ment challenge. The treatm
A 44-year-old white man was diagnosed with chronic hepatitis B in 1999 by his primary-care physician. His laboratory results were as follows: aspartate aminotransferase (AST) 144 IU/L, alanine aminotransferase (ALT) 82 IU/L, hepatitis B surface antigen (HBsAg) positive, hepatitis B e antigen (HBeAg)
Hepatitis E virus (HEV) infection is known to run a self-limited course. Recently, chronic hepatitis E has been described in several immunosuppressed patients after solid organ transplantation. The prevalence of HEV infection after transplantation, however, is unknown. We studied HEV parameters [HEV
However, the authors failed to highlight other important results in their pilot study, that should be incorporated in the design of any future trial testing the validity of these preliminary findings. As noted by HEPATOLOGY Elsewhere 219 this heroic intervention cost-effective? In the end, in which
Hepatitis E virus (HEV) infection induces self-limiting liver disease in immunocompetent individuals. Cases of chronic hepatitis E have recently been identified in organ transplant recipients. We questioned if chronic hepatitis E plays a role in graft hepatitis after liver transplantation in a low e